Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectives.

MedStar author(s):
Citation: Pharmacogenomics. 24(16):859-870, 2023 Nov.PMID: 37942634Institution: MedStar Institute for Innovation | MedStar Washington Hospital CenterDepartment: Associate Dean for Research Development | MedStar Health | National Center for Human Factors in Healthcare | Pharmacogenomics | Pharmacy ResidencyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Pharmacogenetics | *Pharmacogenomic Testing | Humans | Medical Oncology | Pharmacogenetics/ed [Education]Year: 2023ISSN:
  • 1462-2416
Name of journal: PharmacogenomicsAbstract: Aim: Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials & methods: A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System. Results: 25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394). Conclusion: Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.All authors: Bhatt M, Peshkin BN, Kazi S, Schwartz MD, Ashai N, Swain SM, Smith DMFiscal year: FY2024Digital Object Identifier: ORCID: Date added to catalog: 2024-01-16
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 37942634 Available 37942634

Aim: Identify oncology healthcare providers' attitudes toward barriers to and use cases for pharmacogenomic (PGx) testing and implications for prescribing anticancer and supportive care medications. Materials & methods: A questionnaire was designed and disseminated to 71 practicing oncology providers across the MedStar Health System. Results: 25 of 70 (36%) eligible oncology providers were included. 88% were aware of PGx testing and 72% believed PGx can improve care. Of providers who had ordered a medication with PGx implications in the past month, interest in PGx for anticancer (90-100%) and supportive care medications (>75%) was high. Providers with previous PGx education were more likely to have ordered a test (odds ratio: 7.9; 95% CI: 1.1-56; p = 0.0394). Conclusion: Oncology provider prescribing practices and interest in PGx suggest opportunities for implementation.

English

Powered by Koha